Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma

Abstract

SummaryThe optimal treatment strategy for newly diagnosed primary central nervous system lymphoma (PCNSL) has yet to be established, especially in the elderly. In the current study, we conducted a phase II study to evaluate the efficacy and safety of rituximab plus high‐dose MTX followed by rituximab plus cytarabine in patients aged ≥60 years newly diagnosed with PCNSL. Patients received an induction treatment of high‐dose methotrexate plus rituximab followed by two cycles of a consolidation treatment of cytarabine plus rituximab. The primary end‐point was a 2‐year progression‐free survival (PFS) rate. A total of 35 patients were recruited, and their median age was 73 (range: 60–81). After induction treatment, the complete and partial responses (PRs) were 56% and 20% respectively. Twenty‐six patients proceeded to the consolidation treatment; the complete and PRs were 59% and 9% respectively. After a median follow‐up duration of 36.0 months, the 2‐year PFS rate was 58.7%. Treatment was generally well‐tolerated as only three patients were withdrawn from the study due to toxicity, and no treatment‐related mortality was reported. The 2‐year overall survival rate was 77.9%. The current study may suggest the feasibility of administering high‐dose MTX plus cytarabine in PCNSL patients aged ≥60 years and the potential role of additive rituximab.